News BioInvent International AB

Equities

BINV

SE0015244520

Market Closed - Nasdaq Stockholm Other stock markets 11:29:34 2024-04-17 am EDT			5-day change	1st Jan Change
21.5 ^SEK	+2.63%		+16.22%	+13.40%

Apr. 03	BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	MT
Feb. 22	Transcript : BioInvent International AB, 2023 Earnings Call, Feb 22, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioInvent International AB publishes Annual Report 2023	Apr. 04	AQ
BioStock: BioInvent deepens collaboration with MSD	Apr. 04	AQ
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA	Apr. 03	AQ
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	Apr. 03	MT
BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	Apr. 02	PU
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	Apr. 02	AQ
Notice to Annual General Meeting in BioInvent International AB	Mar. 27	AQ
BioStock: BioInvent's CEO comments on the study success in China	Mar. 11	AQ
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China	Mar. 06	AQ
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	Mar. 05	PU
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China	Mar. 05	AQ
BioInvent International AB Year-end report January 1, December 31, 2023	Feb. 23	AQ
BioInvent Q4 2023 - Now a mid-stage clinical company	Feb. 23	AQ
Transcript : BioInvent International AB, 2023 Earnings Call, Feb 22, 2024	Feb. 22
BioInvent International AB Year-end report January 1 – December 31, 2023	Feb. 22	AQ
BioInvent International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
BioInvent International AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Invitation to presentation of BioInvent's Year-end report 2023	Feb. 21	AQ
Invitation to presentation of BioInvent’s Year-end report 2023	Feb. 20	AQ
BioInvent to evaluate BI-1206 in combination with rituximab and Calquence	Feb. 09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioInvent International AB

Equities

BINV

SE0015244520

Summary

Filters